Implantable device actuated by manual button clicks for noninvasive self‐drug administration
暂无分享,去创建一个
Y. B. Choy | Seung Ho Lee | Y. Cho | Se-Na Kim | Cho Rim Kim | Han Bi Ji | C. Lee | Chang Hee Min | B. Shin | Min Ji Kim | Jae Hoon Han | Young Min Cho
[1] David R Owens,et al. Insulin glargine , 2022, Reactions Weekly.
[2] I. Hirsch,et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.
[3] J. Rantanen,et al. Integration of personalized drug delivery systems into digital health. , 2021, Advanced drug delivery reviews.
[4] T. Hansen,et al. An integrative review on facilitators and barriers in delivering and managing injectable therapies in chronic conditions: A part of the ACNAP project ‘injectable medicines among patients with cardiovascular conditions’ , 2020, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.
[5] Chang Ho Ahn,et al. Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist. , 2020, Journal of controlled release : official journal of the Controlled Release Society.
[6] Yuqing Wang,et al. Investigation on the Cooperative Grasping Capabilities of Human Thumb and Index Finger , 2019, Front. Neurorobot..
[7] Chun Gwon Park,et al. Implantable multireservoir device with stimulus-responsive membrane for on-demand and pulsatile delivery of growth hormone , 2019, Proceedings of the National Academy of Sciences.
[8] Johan N. Siebert,et al. A mobile device application to reduce medication errors and time to drug delivery during simulated paediatric cardiopulmonary resuscitation: a multicentre, randomised, controlled, crossover trial. , 2019, The Lancet. Child & adolescent health.
[9] W. Kernan,et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetologia.
[10] M. Rogers,et al. The fear of needles: A systematic review and meta‐analysis , 2018, Journal of advanced nursing.
[11] Guang Wang,et al. The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study , 2018, Diabetes Therapy.
[12] Shane Saunderson,et al. Chronic Disease and Self-Injection: Ethnographic Investigations into the Patient Experience During Treatment , 2017, Rheumatology and Therapy.
[13] Young Bin Choy,et al. Implantable batteryless device for on-demand and pulsatile insulin administration , 2017, Nature Communications.
[14] J. Lykkesfeldt,et al. Chronic Hyperinsulinaemic Hypoglycaemia in Rats Is Accompanied by Increased Body Weight, Hyperleptinaemia, and Decreased Neuronal Glucose Transporter Levels in the Brain , 2017, International journal of endocrinology.
[15] M. Liang,et al. Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences , 2016, Current Rheumatology Reports.
[16] T. Okamura,et al. Relationship between outpatient visit frequency and hypertension control: a 9-year occupational cohort study , 2016, Hypertension Research.
[17] Ellis Meng,et al. A Wireless Implantable Micropump for Chronic Drug Infusion Against Cancer. , 2016, Sensors and actuators. A, Physical.
[18] Hairong Zheng,et al. A Disposable Microfluidic Device for Controlled Drug Release from Thermal-Sensitive Liposomes by High Intensity Focused Ultrasound , 2015, Theranostics.
[19] H. Miura. Historical Changes in Home Care Service and Its Future Challenges. , 2015, Japan Medical Association journal : JMAJ.
[20] Thomas Stieglitz,et al. Biocompatibility evaluation of parylene C and polyimide as substrates for peripheral nerve interfaces , 2015, 2015 7th International IEEE/EMBS Conference on Neural Engineering (NER).
[21] M. Trautmann,et al. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. , 2015, Mayo Clinic proceedings.
[22] A. T. Sidambe,et al. Biocompatibility of Advanced Manufactured Titanium Implants—A Review , 2014, Materials.
[23] Zhigang Suo,et al. Ultrasound-triggered disruption and self-healing of reversibly cross-linked hydrogels for drug delivery and enhanced chemotherapy , 2014, Proceedings of the National Academy of Sciences.
[24] Robert Langer,et al. Near-infrared–actuated devices for remotely controlled drug delivery , 2014, Proceedings of the National Academy of Sciences.
[25] Youxin Li,et al. Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres. , 2013, International journal of pharmaceutics.
[26] Yeun-Ho Joung,et al. Development of Implantable Medical Devices: From an Engineering Perspective , 2013, International neurourology journal.
[27] R. Stout,et al. Jet injection devices for the needle-free administration of compounds, vaccines, and other agents. , 2013, International journal of pharmaceutical compounding.
[28] R. Dore. Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis , 2013, Patient preference and adherence.
[29] J. Meier. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.
[30] Michael E. Cobble,et al. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers , 2012, Vascular health and risk management.
[31] Andrew Taberner,et al. Needle-free jet injection using real-time controlled linear Lorentz-force actuators. , 2012, Medical engineering & physics.
[32] Robert Langer,et al. Reservoir-based drug delivery systems utilizing microtechnology. , 2012, Advanced drug delivery reviews.
[33] M. Cypress,et al. Translating the Research in Insulin Injection Technique , 2012, The Diabetes educator.
[34] Robert Langer,et al. First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip , 2012, Science Translational Medicine.
[35] N. Tan,et al. Initiation of insulin for type 2 diabetes mellitus patients: what are the issues? A qualitative study. , 2011, Singapore medical journal.
[36] A. Turchin,et al. Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. , 2011, Archives of internal medicine.
[37] M. Taskinen,et al. Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes , 2011, Diabetes Care.
[38] Stephanie W. Watts,et al. Drug Delivery: Enabling Technology for Drug Discovery and Development. iPRECIO® Micro Infusion Pump: Programmable, Refillable, and Implantable , 2011, Front. Pharmacol..
[39] M. S. Lewis,et al. Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes , 2011, Annals of Internal Medicine.
[40] D. Keininger,et al. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ) , 2011, Health and quality of life outcomes.
[41] S. Ratcliffe,et al. Needle Anxiety in Children With Type 1 Diabetes and Their Mothers , 2011, MCN. The American journal of maternal child nursing.
[42] Michael A. Gibney,et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations , 2010, Current medical research and opinion.
[43] A. Lugaresi,et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study , 2010, BMC neurology.
[44] L. Pinchuk,et al. Evaluation of an integrated orbital tissue expander in congenital anophthalmos: report of preliminary clinical experience. , 2010, American journal of ophthalmology.
[45] W. Kenneth Ward,et al. Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes , 2010, Diabetes Care.
[46] J. Baynes,et al. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats. , 2010, Biochemical and biophysical research communications.
[47] R. Rubin,et al. Correlates of Insulin Injection Omission , 2010, Diabetes Care.
[48] B.-L. Yu,et al. Cholesterol imbalance in adipocytes: a possible mechanism of adipocytes dysfunction in obesity , 2009, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[49] B. Hartmann,et al. Long‐term exendin‐4 treatment delays natural deterioration of glycaemic control in diabetic Goto–Kakizaki rats , 2009, Diabetes, obesity & metabolism.
[50] M. Linder,et al. In vivo reactions in mice and in vitro reactions in feline cells to implantable microchip transponders with different surface materials , 2009, Veterinary Record.
[51] J. Rosenstock,et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.
[52] R. Khandekar,et al. Regular visits to a diabetes clinic were associated with lower magnitude of visual disability and diabetic retinopathy-a hospital-based historical cohort study in yemen. , 2009, Diabetes technology & therapeutics.
[53] D. Drucker,et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.
[54] A. Fischer,et al. Hematoxylin and eosin staining of tissue and cell sections. , 2008, CSH protocols.
[55] A. Morris,et al. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. , 2007, QJM : monthly journal of the Association of Physicians.
[56] D. Cox,et al. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. , 2006, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[57] A. Young,et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures , 2006, International Journal of Obesity.
[58] A. Baron,et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. , 2005, Endocrinology.
[59] D. Mohr,et al. Self-Injection Anxiety Training: a treatment for patients unable to self-inject injectable medications , 2005, Multiple sclerosis.
[60] R. Gemperli,et al. Evaluation of Cutaneous Abdominal Wall Sensibility After Abdominoplasty , 2005, Aesthetic Plastic Surgery.
[61] S. Cuzzocrea,et al. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. , 2005, Diabetes.
[62] D. Mohr,et al. Managing difficulties with adherence to injectable medications due to blood, injection, and injury phobia and self-injection anxiety , 2003 .
[63] I. Hirsch,et al. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. , 2003, JAMA.
[64] Edmond Sabo,et al. Fear of injections in young adults: prevalence and associations. , 2003, The American journal of tropical medicine and hygiene.
[65] B. Klosterhalfen,et al. Histological analysis of silicone breast implant capsules and correlation with capsular contracture. , 2003, Biomaterials.
[66] D. Mohr,et al. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. , 2002, Journal of behavior therapy and experimental psychiatry.
[67] R. Newson,et al. Injection related anxiety in insulin-treated diabetes. , 1999, Diabetes research and clinical practice.
[68] J. Holst,et al. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats , 1999, Diabetologia.
[69] B. Willershausen,et al. Fear of dental treatment and its possible effects on oral health. , 1999, European journal of medical research.
[70] P. Casadio,et al. Subcutaneous administration of a depot gonadotropin-releasing hormone agonist induces profound reproductive axis suppression in women. , 1998, Fertility and sterility.
[71] Georg Brabant,et al. Pulsatile patterns in hormone secretion , 1992, Trends in Endocrinology & Metabolism.
[72] M J Lichtenstein,et al. Visit frequency for essential hypertension: observed associations. , 1989, The Journal of family practice.
[73] W. Crowley,et al. Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. , 1986, Endocrine reviews.
[74] Yihua Chen,et al. A thermo-degradable hydrogel with light-tunable degradation and drug release. , 2017, Biomaterials.
[75] Christian Lovis,et al. Improving Drugs Administration Safety in Pediatric Resuscitation Using Mobile Technology , 2016, Nursing Informatics.
[76] D. Jain,et al. Implantable Drug Delivery System: A Review , 2012 .
[77] A. Cheng,et al. Emergency treatment of anaphylaxis in infants and children. , 2011, Paediatrics & child health.
[78] H. Bilo,et al. Surgical aspects and complications of continuous intraperitoneal insulin infusion with an implantable pump , 2008, Langenbeck's Archives of Surgery.